Welcome to our dedicated page for Grail SEC filings (Ticker: GRAL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GRAIL, Inc. (Nasdaq: GRAL) files reports with the U.S. Securities and Exchange Commission that provide detail on its operations as a healthcare diagnostics company focused on multi-cancer early detection. On this page, you can review GRAIL’s SEC filings, including current reports on Form 8-K that describe material events such as private placements, equity distribution agreements, commercial leases, preliminary financial results, and strategic collaboration arrangements.
Recent 8-K filings outline securities purchase agreements for private placements of common stock and pre-funded warrants, a stock purchase agreement with Samsung-related entities tied to a planned business collaboration for commercialization of the Galleri test in Asia, and an equity distribution agreement that allows at-the-market offerings of common stock through designated sales agents. Other filings describe a long-term lease for a new corporate headquarters in Sunnyvale, California and the release of quarterly financial results, along with the company’s use of non-GAAP measures such as Adjusted Gross Profit (Loss) and Adjusted EBITDA.
Through these filings, investors can see how GRAIL structures its financings, the key terms of its strategic agreements, and selected information about its financial condition and operations. Stock Titan’s platform adds AI-powered summaries that explain the main points of each filing in plain language, highlight important sections, and help distinguish between one-time transactions and ongoing obligations. Users can also quickly locate information related to equity issuances, registration rights, and other matters that may affect existing or prospective shareholders.
GRAIL, Inc. reported strong 2025 growth while remaining deeply loss-making and released landmark trial data for its Galleri multi-cancer blood test. Full-year revenue rose 17% to
The randomized NHS-Galleri trial in England did not meet its primary endpoint of a statistically significant reduction in combined Stage III–IV cancers, but showed a substantial reduction in Stage IV diagnoses, higher Stage I–II detection and a four-fold higher cancer detection rate when Galleri was added to standard screening. GRAIL completed its Galleri premarket approval submission to the FDA, finished analysis of the 35,000-participant PATHFINDER 2 study, and highlighted a new U.S. Medicare coverage pathway for multi-cancer early detection tests. Based on NHS-Galleri and PATHFINDER 2 results, the company plans to expand its U.S. field sales and medical teams.
Illumina, Inc. filed an amended Schedule 13G showing its beneficial ownership in GRAIL, Inc. common stock has fallen to a minority position. Illumina reports beneficial ownership of 1,302,126 shares of GRAIL common stock, representing 3.2% of the outstanding class, with sole voting and dispositive power over all these shares.
The filing notes that as of December 31, 2025, Illumina beneficially owned 2,502,126 shares, and the 3.2% figure is based on 40,800,541 shares outstanding as of November 14, 2025. Illumina confirms it now holds 5% or less of GRAIL’s common stock.
Baker Bros. Advisors and affiliates reported a 5.3% stake in GRAIL, Inc. common stock. They beneficially own 2,085,333 shares, held through funds 667, L.P. and Baker Brothers Life Sciences, L.P., which together control this position.
The ownership calculation is based on 38,982,223 GRAIL shares outstanding as of November 10, 2025. Part of the position includes pre-funded warrants exercisable at $0.001 per share, but these can only be exercised within limits that cap aggregate beneficial ownership at 4.99%, adjustable up to 19.99% with advance notice.
PRIMECAP Management Co. filed an amended Schedule 13G reporting its beneficial ownership in GRAIL, Inc. as of the event date. The firm reports holding 1,838,684 shares, representing 4.72% of GRAIL’s outstanding common stock, with sole voting power over 1,836,818 shares.
PRIMECAP has sole dispositive power over all 1,838,684 shares and no shared voting or dispositive power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of GRAIL.
GRAIL, Inc. received an updated ownership filing from a group of Farallon-affiliated investment funds and managers. They report beneficial ownership of 2,342,684 shares of GRAIL common stock, including shares underlying 571,021 pre-funded common stock purchase warrants, representing 5.9% of the class as of 12/31/2025.
The warrants carry a 9.99% beneficial ownership cap, but currently do not limit exercise, so all underlying shares are counted as beneficially owned. The amendment also records governance changes: Avner A. Husen is added as a Farallon managing member effective January 1, 2026, while Richard B. Fried, Rajiv A. Patel, and William Seybold ceased such roles effective December 31, 2025 and are no longer deemed beneficial owners.
GRAIL, Inc. director William J. Chase received an equity grant for his board service. On January 15, 2026, he was granted 213 deferred stock units of GRAIL common stock at a price of $97.44 per share, in lieu of $20,794.52 of cash fees otherwise payable for his role as a director.
These awards vest immediately on the grant date, meaning the units are fully earned right away. Following this transaction, Chase beneficially owned 36,803 shares of GRAIL common stock in direct form.
GRAIL, Inc. director Gregory L. Summe received equity compensation instead of cash fees. On January 15, 2026, he was granted 329 deferred stock units of GRAIL common stock, recorded at a price of $97.44 per share, in lieu of $32,136.98 in cash director fees. These awards vest immediately on the grant date and increase his directly held beneficial position to 39,123 shares of common stock. This filing reflects routine director compensation paid in stock units rather than cash.
GRAIL director Steven Mizell received 206 deferred stock units of common stock on January 15, 2026 as director compensation. These units were granted under the company’s deferred stock program and 2024 Incentive Award Plan in lieu of $20,164.38 of cash fees for his board service, using a price of $97.44 per share, which matched the closing market price on the grant date. The awards vest immediately upon grant, meaning they are fully earned right away. Following this grant, Mizell directly beneficially owns 36,675 shares of GRAIL common stock.
GRAIL, Inc. reported that it plans to present a corporate update and preliminary financial information for the quarter and year ended December 31, 2025 at the 2026 J.P. Morgan Healthcare Conference. The company states that the slide presentation to be used at the conference is being furnished as Exhibit 99.1 to this current report. The company clarifies that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, meaning it is not subject to certain liabilities under the Securities Exchange Act and will not be incorporated by reference into other SEC filings unless specifically referenced. The report is signed on behalf of GRAIL by its Chief Financial Officer, Aaron Freidin.
GRAIL, Inc.'s Chief Financial Officer reported an insider sale of company stock. On 12/03/2025, the reporting person sold 25,000 shares of GRAIL common stock in an open market transaction coded "S" (sale). The weighted average sale price was $99.1527 per share, with individual trades executed between $99.00 and $99.76.
After this transaction, the reporting person beneficially owned 259,077 shares of GRAIL common stock, held directly. The footnote explains that the reported price is an average across multiple trades and that detailed trade-level pricing information within the stated range is available upon request.